- Home
- HCA vs REGN Comparison
HCA vs REGN Comparison
Compare HCA & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HCA | REGN |
|---|---|---|
| Founded | 1968 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hospital/Nursing Management | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 105.5B | 77.5B |
| IPO Year | 2009 | 1995 |
Fundamental Metrics
Financial Performance| Metric | HCA | REGN |
|---|---|---|
| Price | $505.20 | $772.70 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 21 | 25 |
| Target Price | $528.00 | ★ $821.08 |
| AVG Volume (30 Days) | ★ 902.6K | 497.8K |
| Earning Date | 04-24-2026 | 04-29-2026 |
| Dividend Yield | ★ 0.64% | 0.49% |
| EPS Growth | ★ 28.77 | 8.19 |
| EPS | 28.33 | ★ 41.48 |
| Revenue | ★ $75,600,000,000.00 | $5,872,227,000.00 |
| Revenue This Year | $5.07 | $12.03 |
| Revenue Next Year | $4.90 | $10.42 |
| P/E Ratio | ★ $17.26 | $18.30 |
| Revenue Growth | 7.08 | ★ 20.82 |
| 52 Week Low | $314.43 | $476.49 |
| 52 Week High | $556.52 | $821.11 |
Technical Indicators
Market Signals| Indicator | HCA | REGN |
|---|---|---|
| Relative Strength Index (RSI) | 54.28 | 54.70 |
| Support Level | $461.74 | $750.69 |
| Resistance Level | $523.78 | $788.69 |
| Average True Range (ATR) | 11.97 | 16.76 |
| MACD | 1.18 | 3.00 |
| Stochastic Oscillator | 97.22 | 84.04 |
Price Performance
Historical ComparisonAbout HCA HCA Healthcare Inc.
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the United States. As of December 2025, the firm owned and operated 190 hospitals and over 2,500 outpatient facillities across 19 states and a small foothold in the United Kingdom.
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).